Opinion

Video

Clinical Perspectives: Use of CDK4/6i After CDK4/6i

Panelists discuss potential treatment options for patients following progression on CDK4/6 inhibitors (i) in HR+/HER2– metastatic breast cancer.

Video Player is loading.
Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected

    Video content above is prompted by the following:

    Dr. Bardia to Dr. Chan: Can you please review the potential options for after CK4/6i progression: